Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrice Viens

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Critical Reviews in Oncology/Hematology|February 22, 2002
High-dose chemotherapy in advanced breast cancerPatrice Viens, Dominique Maraninchi
Oncoscience|January 21, 2017
Bevacizumab in HER2-negative inflammatory breast cancerFrançois Bertucci, Anthony Goncalves, Patrice Viens
The Lancet. Oncology|June 18, 2016
SPAG5: the ultimate marker of proliferation in early breast cancer?François Bertucci, Patrice Viens, Daniel Birnbaum
Expert Review of Anticancer Therapy|May 17, 2017
The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Anthony Gonçalves, Audrey Monneur, Patrice Viens, et al.
Cancer|May 27, 2010
Gene expression profiling of inflammatory breast cancerFrançois Bertucci, Pascal Finetti, Daniel Birnbaum, et al.
The Oncologist|August 21, 2013
Difference in therapeutic response between basal and nonbasal triple-negative breast cancersFrançois Bertucci, Pascal Finetti, Patrice Viens, et al.
Bulletin Du Cancer|December 6, 2014
[Systemic treatments of inflammatory breast cancer: an overview]Audrey Monneur, François Bertucci, Patrice Viens, et al.
Cancer|May 27, 2010
Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experiencePatrice Viens, Carole Tarpin, Henri Roche, et al.
Cancer Letters|September 15, 2014
EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancerFrançois Bertucci, Pascal Finetti, Patrice Viens, et al.
Bulletin Du Cancer|September 13, 2007
[Prostate cancer and chemotherapy]Gwenaelle Gravis, Naji Salem, Franck Bladou, et al.
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Critical Reviews in Oncology/Hematology|February 22, 2002
High-dose chemotherapy in advanced breast cancerPatrice Viens, Dominique Maraninchi
Oncoscience|January 21, 2017
Bevacizumab in HER2-negative inflammatory breast cancerFrançois Bertucci, Anthony Goncalves, Patrice Viens
The Lancet. Oncology|June 18, 2016
SPAG5: the ultimate marker of proliferation in early breast cancer?François Bertucci, Patrice Viens, Daniel Birnbaum
Expert Review of Anticancer Therapy|May 17, 2017
The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Anthony Gonçalves, Audrey Monneur, Patrice Viens, et al.
Cancer|May 27, 2010
Gene expression profiling of inflammatory breast cancerFrançois Bertucci, Pascal Finetti, Daniel Birnbaum, et al.
The Oncologist|August 21, 2013
Difference in therapeutic response between basal and nonbasal triple-negative breast cancersFrançois Bertucci, Pascal Finetti, Patrice Viens, et al.
Bulletin Du Cancer|December 6, 2014
[Systemic treatments of inflammatory breast cancer: an overview]Audrey Monneur, François Bertucci, Patrice Viens, et al.
Cancer|May 27, 2010
Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experiencePatrice Viens, Carole Tarpin, Henri Roche, et al.
Cancer Letters|September 15, 2014
EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancerFrançois Bertucci, Pascal Finetti, Patrice Viens, et al.
Bulletin Du Cancer|September 13, 2007
[Prostate cancer and chemotherapy]Gwenaelle Gravis, Naji Salem, Franck Bladou, et al.
Pageof 18